VERU INC.
About VERU INC.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $16.9M
- Net income
- -$22.7M
- Total assets
- $29.8M
- Market cap
- $54.6M
- Operating margin
- -229.6%
- Net margin
- -145.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.8M
- Operating expenses
- $35.5M
- Operating income
- -$24.8M
- Income tax
- -$1.9K
- Net income
- -$15.7M
- EPS (basic)
- $-1.55
Balance sheet
- Total assets
- $29.8M
- Current assets
- $18.9M
- Total liabilities
- $11.5M
- Current liabilities
- $7.8M
- Shareholders’ equity
- $18.3M
Cash flow
- Operating cash flow
- -$30.0M
- Investing cash flow
- $25.1M
- Financing cash flow
- -$4.2M
- Net cash flow
- -$9.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $54.6M
- Dividend yield
- 9.33%
- Shares outstanding
- 18.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 1, 1990
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.7M in FY2024.
- Revenue declined 82% from FY2021 to FY2025.
- Trading 57% below its 52-week high.
- Pays a dividend yielding about 9.33% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review VERU INC..
Write a review
News about VERU INC.
News & sentiment via Polygon.io
